Acute interstitial lung disease in a patient with ulcerative colitis: Case report and literature review
More details
Hide details
1st Pneumonology Department, General Hospital “G. Papanikolaou”, Thessaloniki
Pneumonology Department, Regional General Hospital, Serres
Corresponding author
Antonis Antoniadis   

Pneumonology Clinic General Hospital of Serres
Pneumon 2012;25(3):319-324
Mesalazine is widely used for the treatment of idiopathic inflammatory bowel diseases (IIBD), such as Crohn’s disease and ulcerative colitis. Mesalazine-induced alveolitis is extremely rare, and discrimination between drug-related adverse events and pulmonary manifestations of IIBD is difficult. The case is reported of a 45 year-old female with a history of ulcerative colitis, on treatment mesalazine 500mg three times daily for 10 months, and p-ANCA meningomyeloradiculitis, treated with prednisolone, who presented with fever and symptoms of acute respiratory failure. Differential diagnosis included pulmonary manifestations of ulcerative colitis, mesalazine-induced lung toxicity, opportunistic infection, p-ANCA vasculitis and thromboembolic disease. Pulmonary function tests revealed a restrictive pattern with reduced carbon monoxide diffusing capacity, and high resolution computed tomography of the chest showed findings compatible with acute interstitial lung disease. Discontinuation of mesalazine and replacement of oral by iv corticosteroid administration resulted in rapid improvement in the symptoms, radiological findings and pulmonary function tests.
Jones GR, Malone DNS. Sulphasalazine induced lung disease. Thorax. 1972; 27(6):713–717.
Pigakis K, Ferdoutsis M, Meletis G, Patsourakis G, Bachlitzanakis N. Pulmonary toxicity from cardiovascular drugs. Pneumon 2009; 22(1): 75-84.
Tromm A, Griga T, May B. Oral mesalazine for the treatment of Crohn’s disease: clinical efficacy with respect to pharmacokinetic properties. Hepatogastroenterology 1999; 46:3124-3135.
Small RE, Schraa CC. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease. Pharmacotherapy. 1994;14(4):385-98.
Liptay S, Bachem M, Häcker G, Adler G, Debatin KM, Schmid RM. Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol. 1999; 128(7):1361-9.
Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002; 51(4):536-9.
Bitton A, Peppercorn MA, Hanrahan JP, Upton MP. Mesalamineinduced lung toxicity. Am J Gastroenterol. 1996; 91(5):1039-40.
Katsenos S, Psathakis K, Kokkonouzis I, Panagou P, Tsintiris K, Bouros D. Drug-induced pulmonary toxicity in a patient treated with mesalazine and azathioprine for ulcerative colitis. Acta Gastroenterol Belg. 2007; 70(3):290-2.
Welte T, Hamm H, Fabel H. Mesalazine alveolitis. Lancet. 1991; 338(8777):1273.
Sesin GP, Mucciardi N, Almeida S. Mesalamine-associated pleural effusion with pulmonary infiltration. Am J Health Syst Pharm. 1998; 55(21):2304-5.
Lim AG, Hine KR. Fever, vasculitic rash, arthritis, pericarditis, and pericardial effusion after mesalazine. BMJ 1994; 308(6921):113.
Honeybourne D. Mesalazine toxicity. BMJ 1994; 308(6927):533-4.
Actis GC, Ottobrelli A, Baldi S, Scappaticci E, Modena V, Fusaro E, Mengozzi G, Rizzetto M. Mesalamine-induced lung injury in a patient with ulcerative colitis and a confounding autoimmune background: a case report. Mt Sinai J Med. 2005; 72(2): 136-40.
Saltzman K, Rossoff LJ, Gouda H, Tongia S. Mesalamine-induced unilateral eosinophilic pneumonia. Am J Roentgenol. 2001; 177(1):257.
Nguyen TM, Le Gall C, Lachaux A, Boulieu R. High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine. Int J Clin Pharmacol Ther. 2010 Apr;48(4):275-81.
Nanayakkara PW, de Jong E, Postmus PE. Bilateral pulmonary infiltrates in a patient with ulcerative colitis receiving mesalazine. Eur J Intern Med. 2004; 15(7):470-472.
Reinoso MA, Schroeder KW, Pisani RJ. Lung disease associated with orally administered mesalamine for ulcerative colitis. Chest. 1992;101(5):1469-71.
Muzzi A, Ciani F, Bianchini D, Festini G, Volpe C. Adverse pulmonary effects of mesalamine. Chest. 1995; 108(4):1181.
Sviri S, Gafanovich I, Kramer MR, Tsvang E, Ben-Chetrit E. Mesalamine-induced hypersensitivity pneumonitis. A case report and review of the literature. J Clin Gastroenterol. 1997; 24(1):34-6.
Tanigawa K, Sugiyama K, Matsuyama H, Nakao H, Kohno K, Komuro Y, Iwanaga Y, Eguchi K, Kitaichi M, Takagi H. Mesalazineinduced eosinophilic pneumonia. Respiration. 1999; 66(1):69-72.
le Gros V, Saveuse H, Lesur G, Brion N. Lung and skin hypersensitivity to 5-aminosalicylic acid. BMJ. 1991; 302(6782):970.
Foster RA, Zander DS, Mergo PJ, Valentine JF. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis. 2003; 9(5):308-15.
Hesselmann J, Kuhn M, Ostendorf PC, Huep WW. Acute alveolitis in ulcerative colitis: extra-intestinal organ complication or drug side effect. Leber Magen Darm. 1991; 21(1):26-8, 31.
Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine. 1976; 55(5): 401-12.
Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine. 1993;72(3):151-83.
Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004; 71:301-326.
Journals System - logo
Scroll to top